PD24-05 IMPACT OF ABIRATERONE ACETATE IN THE POST-DOCETAXEL SETTING ON THE SURVIVAL OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: A POPULATION-BASED STUDY IN QUEBEC

Abstract

You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) I1 Apr 2017PD24-05 IMPACT OF ABIRATERONE ACETATE IN THE POST-DOCETAXEL SETTING ON THE SURVIVAL OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: A POPULATION-BASED STUDY IN QUEBEC Alice Dragomir, Joice Rocha, Marie Vanhuyse, Fabio Cury, Jason Hu, Noémie Prévost, and Armen Aprikian Alice DragomirAlice Dragomir More articles by this author , Joice RochaJoice Rocha More articles by this author , Marie VanhuyseMarie Vanhuyse More articles by this author , Fabio CuryFabio Cury More articles by this author , Jason HuJason Hu More articles by this author , Noémie PrévostNoémie Prévost More articles by this author , and Armen AprikianArmen Aprikian More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.1082AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Abiraterone was introduced in Quebec in 2012 for metastatic castration-resistant prostate cancer (mCRPC) in the post-docetaxel setting. This study described abiraterone utilization in the early post-approval period and its clinical effectiveness in Quebec, for both post-chemotherapy patients and patients unfit for chemotherapy. METHODS A retrospective cohort study was conducted using Quebec public healthcare administrative databases. The study population consisted of men 40 years and older with a diagnosis of prostate cancer (PCa), and who received androgen-deprivation therapy (ADT) (orchiectomy or luteinizing hormone-releasing hormone analogs or antagonists (LHRHa)) between January 2001 and July 2013. In addition, patients should have received a first treatment of abiraterone between 2012 and 2013. Treatment groups were defined as: 1) Abiraterone post chemotherapy and 2) Abiraterone “exception patient”, for chemotherapy-ineligible patients treated with abiraterone authorized by the “exception patient” measure category. Study outcomes included overall survival since abiraterone initiation, abiraterone duration, and hospitalization days. Cox proportional hazard regression was used to estimate the effectiveness of abiraterone in the post-docetaxel setting adjusted for several covariates. RESULTS Our cohort consisted of 303 mCRPC patients treated with abiraterone (abiraterone post-chemotherapy: 99 and abiraterone “exception patient”: 204). The median age was 75.0 for the abiraterone post-chemotherapy group and 80.0 for the abiraterone “exception patient” group. The corresponding median survivals were 12 and 14 months, respectively (log-rank test p-value=0.815). Risk of death was similar in the abiraterone post-chemotherapy and abiraterone “exception patient” groups (hazard ratio (HR): 0.89; 95%CI 0.57-1.38). CONCLUSIONS Effectiveness of abiraterone in older patients who were chemotherapy ineligible was similar to that of patients with prior docetaxel exposure. Overall, real-world survival benefits of abiraterone were similar to the results of the COU-AA-301 trial. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e453 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Alice Dragomir More articles by this author Joice Rocha More articles by this author Marie Vanhuyse More articles by this author Fabio Cury More articles by this author Jason Hu More articles by this author Noémie Prévost More articles by this author Armen Aprikian More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...